| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6670351 | SAVIENT PHARMS | Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1 |
Oct, 2012
(11 years ago) | |
| US6090799 | SAVIENT PHARMS | Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1 |
Jul, 2017
(6 years ago) | |
| US6828313 | SAVIENT PHARMS | Use of oxandrolone in the treatment of burns and other wounds |
Dec, 2017
(6 years ago) | |
| US5872147 | SAVIENT PHARMS | Use of oxandrolone in the treatment of chronic obstructive pulmonary disease |
Dec, 2017
(6 years ago) | |
| US6576659 | SAVIENT PHARMS | Use of oxandrolone in the treatment of burns an other wounds |
Dec, 2017
(6 years ago) | |
Oxandrin is owned by Savient Pharms.
Oxandrin contains Oxandrolone.
Oxandrin has a total of 5 drug patents out of which 5 drug patents have expired.
Expired drug patents of Oxandrin are:
- US6670351
- US6090799
- US6828313
- US5872147
- US6576659
Oxandrin was authorised for market use on 05 November, 2001.
Oxandrin is available in tablet;oral dosage forms.
Oxandrin can be used as to promote weight gain after weight loss in certain types of patients.
The generics of Oxandrin are possible to be released after 05 December, 2017.
Drugs and Companies using OXANDROLONE ingredient
Market Authorisation Date: 05 November, 2001
Treatment: To promote weight gain after weight loss in certain types of patients
Dosage: TABLET;ORAL
How can I launch a generic of OXANDRIN before it's drug patent expiration?
More Information on Dosage
OXANDRIN family patents
